Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald lowered shares of Arrowhead Pharmaceuticals from an overweight rating to a neutral rating and set a $24.00 price target for the company. in a research report on Thursday, June 27th. B. Riley upped their price target on shares of Arrowhead Pharmaceuticals from $32.00 to $46.00 and gave the stock a buy rating in a research report on Monday, August 19th. ValuEngine lowered shares of Arrowhead Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Thursday, August 1st. Piper Jaffray Companies upped their price target on shares of Arrowhead Pharmaceuticals from $33.00 to $50.00 and gave the stock an overweight rating in a research report on Tuesday, August 6th. Finally, TheStreet raised shares of Arrowhead Pharmaceuticals from a d rating to a c+ rating in a research report on Thursday, May 30th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Arrowhead Pharmaceuticals has an average rating of Buy and a consensus price target of $33.70.
Shares of ARWR stock opened at $30.88 on Thursday. Arrowhead Pharmaceuticals has a one year low of $10.41 and a one year high of $35.41. The company has a 50 day moving average price of $29.18 and a 200 day moving average price of $22.77. The firm has a market capitalization of $3.05 billion, a price-to-earnings ratio of 69.83 and a beta of 1.59.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported $0.21 EPS for the quarter, missing the consensus estimate of $0.34 by ($0.13). Arrowhead Pharmaceuticals had a return on equity of 26.27% and a net margin of 33.28%. The company had revenue of $42.70 million for the quarter, compared to analyst estimates of $59.05 million. Sell-side analysts anticipate that Arrowhead Pharmaceuticals will post 0.73 earnings per share for the current fiscal year.
In other news, Director Mauro Ferrari sold 17,756 shares of the stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $27.61, for a total value of $490,243.16. Following the completion of the sale, the director now owns 1,900 shares of the company’s stock, valued at $52,459. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Patrick O’brien sold 30,000 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $24.88, for a total transaction of $746,400.00. Following the completion of the sale, the general counsel now directly owns 203,000 shares of the company’s stock, valued at approximately $5,050,640. The disclosure for this sale can be found here. 4.80% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers grew its holdings in Arrowhead Pharmaceuticals by 7.2% during the 1st quarter. Rhumbline Advisers now owns 124,276 shares of the biotechnology company’s stock valued at $2,280,000 after purchasing an additional 8,313 shares in the last quarter. Bank of America Corp DE grew its holdings in Arrowhead Pharmaceuticals by 812.8% during the 4th quarter. Bank of America Corp DE now owns 333,938 shares of the biotechnology company’s stock valued at $4,148,000 after purchasing an additional 380,784 shares in the last quarter. Virginia Retirement Systems ET AL acquired a new stake in Arrowhead Pharmaceuticals during the 1st quarter valued at $391,000. Bailard Inc. grew its holdings in Arrowhead Pharmaceuticals by 50.5% during the 1st quarter. Bailard Inc. now owns 165,600 shares of the biotechnology company’s stock valued at $3,039,000 after purchasing an additional 55,600 shares in the last quarter. Finally, Strs Ohio grew its holdings in Arrowhead Pharmaceuticals by 109.5% during the 2nd quarter. Strs Ohio now owns 26,400 shares of the biotechnology company’s stock valued at $699,000 after purchasing an additional 13,800 shares in the last quarter. 73.52% of the stock is owned by institutional investors.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Recommended Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.